Triochem Products Ltd
Triochem Products engaged primarily in the business of manufacturer and exporter of pharlnaceuticals products, Apls and chemicals.
- Market Cap ₹ Cr.
- Current Price ₹ 17.4
- High / Low ₹ /
- Stock P/E
- Book Value ₹ 566
- Dividend Yield 0.00 %
- ROCE -3.32 %
- ROE -4.38 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.03 times its book value
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of -4.32% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 33.74 | 30.68 | 23.11 | 18.06 | 34.99 | 12.35 | 20.03 | 13.94 | 8.82 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 32.38 | 29.44 | 22.11 | 17.07 | 31.18 | 10.71 | 15.48 | 14.30 | 7.47 | 1.33 | 1.05 | 1.22 | 1.50 | |
| Operating Profit | 1.36 | 1.24 | 1.00 | 0.99 | 3.81 | 1.64 | 4.55 | -0.36 | 1.35 | -1.33 | -1.05 | -1.22 | -1.50 |
| OPM % | 4.03% | 4.04% | 4.33% | 5.48% | 10.89% | 13.28% | 22.72% | -2.58% | 15.31% | ||||
| 0.21 | 0.08 | -0.01 | 0.16 | 0.41 | 0.06 | 0.47 | 0.13 | 0.55 | 0.27 | -0.19 | 1.05 | 1.06 | |
| Interest | 0.47 | 0.45 | 0.20 | 0.07 | 0.40 | 0.46 | 0.30 | 0.21 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.31 | 0.32 | 0.27 | 0.28 | 0.25 | 0.21 | 0.17 | 0.14 | 0.12 | 0.11 | 0.09 | 0.08 | 0.07 |
| Profit before tax | 0.79 | 0.55 | 0.52 | 0.80 | 3.57 | 1.03 | 4.55 | -0.58 | 1.76 | -1.17 | -1.33 | -0.25 | -0.51 |
| Tax % | 32.91% | 23.64% | 32.69% | 28.75% | 28.57% | 29.13% | 25.27% | -24.14% | 25.00% | -24.79% | -24.06% | 60.00% | |
| 0.53 | 0.42 | 0.34 | 0.58 | 2.56 | 0.74 | 3.40 | -0.45 | 1.32 | -0.89 | -1.01 | -0.40 | -0.80 | |
| EPS in Rs | 21.63 | 17.14 | 13.88 | 23.67 | 104.49 | 30.20 | 138.78 | -18.37 | 53.88 | -36.33 | -41.22 | -16.33 | -32.66 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -376% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | -1% |
| 3 Years: | -4% |
| Last Year: | -4% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 |
| Reserves | 3.89 | 4.31 | 4.65 | 5.24 | 7.79 | 8.53 | 11.93 | 11.47 | 12.80 | 11.35 | 14.38 | 13.42 | 13.62 |
| 4.78 | 3.50 | 0.00 | 2.86 | 2.28 | 5.79 | 2.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 2.00 | 0.42 | 2.12 | 1.93 | 1.47 | 0.58 | 1.94 | 0.38 | 0.28 | 0.24 | 0.25 | 0.23 | 0.24 | |
| Total Liabilities | 10.92 | 8.48 | 7.02 | 10.28 | 11.79 | 15.15 | 16.62 | 12.10 | 13.33 | 11.84 | 14.88 | 13.90 | 14.11 |
| 2.04 | 1.72 | 1.85 | 1.64 | 1.42 | 1.22 | 1.06 | 0.94 | 0.87 | 0.77 | 0.68 | 0.60 | 0.57 | |
| CWIP | 0.22 | 0.37 | 0.04 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.12 | 0.12 | 3.68 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.42 | 11.07 | 10.63 | 11.22 |
| 8.54 | 6.27 | 1.45 | 8.64 | 10.37 | 13.93 | 15.53 | 11.13 | 12.46 | 1.65 | 3.13 | 2.67 | 2.32 | |
| Total Assets | 10.92 | 8.48 | 7.02 | 10.28 | 11.79 | 15.15 | 16.62 | 12.10 | 13.33 | 11.84 | 14.88 | 13.90 | 14.11 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.20 | 2.34 | 6.79 | -6.48 | 1.45 | -3.75 | 3.82 | 10.25 | 3.47 | -1.03 | -3.76 | 0.20 | |
| -0.09 | -0.10 | -3.70 | 3.71 | -0.01 | 0.02 | -0.03 | 0.00 | 0.16 | -9.82 | 3.34 | 0.17 | |
| -11.83 | -1.69 | -3.68 | 2.80 | -0.92 | 3.06 | -3.49 | -2.61 | -0.02 | 0.00 | 0.00 | 0.00 | |
| Net Cash Flow | 0.28 | 0.56 | -0.59 | 0.03 | 0.52 | -0.67 | 0.30 | 7.64 | 3.61 | -10.85 | -0.42 | 0.37 |
| Free Cash Flow | 12.11 | 2.24 | 6.68 | -6.51 | 1.42 | -3.76 | 3.79 | 10.23 | 3.44 | -1.03 | -3.76 | 0.20 |
| CFO/OP | 899% | 241% | 682% | -635% | 56% | -176% | 106% | -2,939% | 287% | 105% | 351% | -17% |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 25.31 | 2.02 | 0.00 | 49.52 | 0.00 | 98.42 | 225.96 | 36.40 | 0.00 | |||
| Inventory Days | 57.87 | 55.65 | 5.85 | 52.93 | 104.38 | 414.36 | 41.57 | 24.60 | 2.90 | 0.00 | ||
| Days Payable | 10.14 | 1.45 | 31.02 | 36.57 | 9.13 | 14.72 | 19.85 | 9.26 | 9.85 | |||
| Cash Conversion Cycle | 73.05 | 56.22 | -25.17 | 65.88 | 95.24 | 498.06 | 247.68 | 51.74 | -6.95 | |||
| Working Capital Days | 22.50 | 16.06 | -19.43 | 63.06 | 56.23 | 216.64 | 190.79 | 63.10 | 0.83 | |||
| ROCE % | 8.78% | 11.78% | 11.57% | 12.83% | 42.53% | 11.97% | 33.16% | -2.80% | 14.45% | -10.14% | -2.67% | -3.32% |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|
| Electricity Consumption per unit of production (Bulk Drug, APIs) Units/unit |
|
||
| Export Earnings INR Lakhs |
|||
| Furnace Oil Consumption per unit of production (Bulk Drug, APIs) Units/unit |
|||
| Total Electricity Purchased Units |
|||
| Total Furnace Oil Purchased Liters |
|||
| Number of Factories Number |
|||
Documents
Announcements
-
Board Meeting Outcome for Outcome Of The Independent Director'S Meeting - Pursuant To Regulation 25(3) Of The SEBI (Listing Obligations And Disclosures Requirements) Regulation, 2015
20 Mar - Independent Directors met 20 Mar 2026, reviewed board and chair performance, information flow; meeting 3:00–4:10 PM.
- Closure of Trading Window 19 Mar
-
Compliance-57 (4) : Prior intimation to the beginning of the quarter
19 Mar - NIL Reg 57 compliance: no debt securities; no interest due Apr–Jun 2026.
-
Board Meeting Intimation for Intimation Separate Board Meeting Of Independent Director'S Under Regulation 25(3) Of The SEBI (LODR) Regulations, 2015
13 Mar - Independent Directors' meeting 20 Mar 2026, 3:00 PM to review board and chairman performance.
- Re-Submission Of Unaudited Standalone Financial Results For The Quarter And Nine Months Ended 31St December 2025. Refer Your Email Dated 20Th February 2026 23 Feb
Annual reports
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse